SG11202008162WA - Heteroaryl compounds as type ii irak inhibitors and uses hereof - Google Patents

Heteroaryl compounds as type ii irak inhibitors and uses hereof

Info

Publication number
SG11202008162WA
SG11202008162WA SG11202008162WA SG11202008162WA SG11202008162WA SG 11202008162W A SG11202008162W A SG 11202008162WA SG 11202008162W A SG11202008162W A SG 11202008162WA SG 11202008162W A SG11202008162W A SG 11202008162WA SG 11202008162W A SG11202008162W A SG 11202008162WA
Authority
SG
Singapore
Prior art keywords
type
heteroaryl compounds
irak inhibitors
uses hereof
hereof
Prior art date
Application number
SG11202008162WA
Other languages
English (en)
Inventor
Catherine Jorand-Lebrun
Nadia Brugger
Theresa Johnson
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202008162WA publication Critical patent/SG11202008162WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202008162WA 2018-04-05 2019-04-01 Heteroaryl compounds as type ii irak inhibitors and uses hereof SG11202008162WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652981P 2018-04-05 2018-04-05
PCT/EP2019/058186 WO2019192962A1 (en) 2018-04-05 2019-04-01 Heteroaryl compounds as type ii irak inhibitors and uses hereof

Publications (1)

Publication Number Publication Date
SG11202008162WA true SG11202008162WA (en) 2020-09-29

Family

ID=66165920

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008162WA SG11202008162WA (en) 2018-04-05 2019-04-01 Heteroaryl compounds as type ii irak inhibitors and uses hereof

Country Status (13)

Country Link
US (1) US11873303B2 (ko)
EP (1) EP3774797A1 (ko)
JP (1) JP7328987B6 (ko)
KR (1) KR20200140302A (ko)
CN (1) CN112236429A (ko)
AU (1) AU2019249721A1 (ko)
BR (1) BR112020018383A2 (ko)
CA (1) CA3092625A1 (ko)
IL (1) IL277408B1 (ko)
MX (1) MX2020009234A (ko)
SG (1) SG11202008162WA (ko)
TW (1) TW202005968A (ko)
WO (1) WO2019192962A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
AU2020355359B2 (en) * 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
WO2021226547A2 (en) * 2020-05-08 2021-11-11 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
MX2022013984A (es) * 2020-05-08 2023-01-30 Halia Therapeutics Inc Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CA3186041A1 (en) * 2020-06-08 2021-12-16 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
WO2022212326A1 (en) * 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
US20230405151A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Use of irak4 modulators for gene therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EA201690952A1 (ru) 2013-11-08 2016-08-31 Такеда Фармасьютикал Компани Лимитед Пиразол для лечения аутоиммунных расстройств
CA2945819A1 (en) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112016029853A2 (pt) * 2014-06-20 2017-08-22 Aurigene Discovery Tech Ltd compostos de indazol substituído como inibidores de irak4
MX2017009624A (es) * 2015-02-06 2017-11-20 Merck Patent Gmbh Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
SG10201911665UA (en) * 2016-04-15 2020-01-30 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US20190203253A1 (en) 2016-07-05 2019-07-04 University Of Saskatchewan Methods of identifying and treating cancer patients with an ephb6 deficiency
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof

Also Published As

Publication number Publication date
EP3774797A1 (en) 2021-02-17
CA3092625A1 (en) 2019-10-10
JP2021520356A (ja) 2021-08-19
IL277408B1 (en) 2024-04-01
BR112020018383A2 (pt) 2020-12-29
CN112236429A (zh) 2021-01-15
US20210163487A1 (en) 2021-06-03
AU2019249721A1 (en) 2020-09-17
WO2019192962A1 (en) 2019-10-10
RU2020135904A (ru) 2022-05-05
JP7328987B2 (ja) 2023-08-17
JP7328987B6 (ja) 2023-10-25
MX2020009234A (es) 2020-10-12
IL277408A (en) 2020-11-30
TW202005968A (zh) 2020-02-01
US11873303B2 (en) 2024-01-16
KR20200140302A (ko) 2020-12-15

Similar Documents

Publication Publication Date Title
SG11202008162WA (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
ZA201801056B (en) Heteroaryl compounds as irak inhibitors and uses thereof
ZA201800975B (en) Heteroaryl compounds as irak inhibitors and uses thereof
IL281319A (en) Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
IL285178A (en) compounds and their use
EP3889150A4 (en) IRAQ INHIBITOR COMPOUND
GB201803568D0 (en) Novel compounds and uses
GB201705971D0 (en) Inhibitor compounds
EP3250035A4 (en) COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS
EP3612532C0 (en) VMAT2 INHIBITORY COMPOUNDS AND COMPOSITIONS THEREOF
EP3681499A4 (en) CONNECTIONS AS RAS INHIBITORS AND THEIR USE
IL285177A (en) compounds and their use
ZA202007547B (en) Heteroaryl compounds and uses thereof
ZA202105752B (en) Haloallylamine compounds and application thereof
IL276352A (en) Quinoline compounds as IRAK inhibitors and uses thereof
IL286497A (en) compounds and their use
IL284764A (en) compounds and their uses
IL285118A (en) compounds and their uses
PT3725791T (pt) Sal que serve como inibidor de akt e seu cristal
ZA202201239B (en) Aminothiolester compounds and uses thereof
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201708502D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds